Navigation Links
Promising new treatment for Alzheimer's suggested based on Hebrew University research
Date:7/20/2009

Research carried out at the Hebrew University of Jerusalem has resulted in a promising approach to help treat Alzheimer's disease in a significant proportion of the population that suffers from a particularly rapid development of this disease.

In the research at the Silberman Institute of Life Sciences of the Hebrew University, scientists solved a mystery as to why people who carried a mutated gene known as BChE-K were prone to more rapid development of Alzheimer's than those who had a normal version of the gene. This mutation appears in about 20 percent of the American and Israeli populations.

In theory, the carriers of the mutated gene should actually be more protected from the devastating effects of the disease, since the mutated protein (the enzyme that is the product of the gene) breaks down the neurotransmitter acetylcholine at a slower rate than in those who have the normal gene. The result is that the carriers maintain higher levels of this neurotransmitter, so they should in principle be protected from Alzheimer's disease, in which acetylcholine levels decrease.

Indeed, these carriers tend to develop the disease later than others, but when that happens, it progresses more rapidly and does not respond to medication. Therefore, the bottom line is that carriers of the mutated gene have a greater risk than others for disease progression. The reason for this anomalous situation has been a puzzle for a long time, but the studies by the Hebrew University scientists solved it by finding the explanation for this increased risk, thereby offering as well a possible new therapeutic solution.

At the Wolfson Center for Structural Biology at the Hebrew University, the researchers found that the mutation in the BChE-K gene damages the very end, or tail, of the resultant mutant enzyme protein. This tail is the part of BChE which is important for protection from the Alzheimer's disease plaques. It does this by interacting with the Alzheimer's disease β-amyloid protein and preventing it from precipitating and forming those brain plaques which are the neuropathological hallmark of this disease.

To compare the normal protein to the K mutant, the researchers used synthetic tails of the normal and the K proteins, as well as engineered human BChE produced in the milk of transgenic goats at a U.S. company, Pharmathene. The goat- produced protein is prepared at Pharmathene for the U.S. military as protection from nerve gas poisoning (a result of earlier research at the Hebrew University). It was much more stable and efficient than the mutant protein, which suggests that the BChE-K carriers' susceptibility to Alzheimer's could be substantially improved by treating them with the engineered normal protein that is produced in the milk of the transgenic goats.


'/>"/>

Contact: Rebecca Zeffert
rebeccaz@savion.huji.ac.il
972-258-81641
The Hebrew University of Jerusalem
Source:Eurekalert

Related biology news :

1. UIC researchers find promising new targets for antibiotics
2. New book defines promising young field of adult neurogenesis
3. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
4. Cancer and arthritis therapy may be promising treatment for diabetes
5. Unique whey protein is promising supplement for strict PKU diet
6. Promising new drug targets identified for Huntingtons disease
7. Promising new nanotechnology for spinal cord injury
8. Biodesigns Rittmann offers promising perspectives on societys energy challenge
9. UIC researchers make promising finding in severe lung disease
10. New treatment approach promising for lymphoma patients in the developing world
11. Immunotherapy in high-risk pediatric sarcomas shows promising response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  Singulex, Inc., the leader in ... entered into a license and supply agreement with Thermo ... agreement provides Singulex access to Thermo Scientific BRAHMS PCT ... is used to diagnose systemic bacterial infection and ... to aid in assessing the risk of critically ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , the ... of its patent portfolio, which grew to over 40 granted and pending ... , , ... filed patent entitled " System, Device, and Method Estimating Force ... enables device makers to forego costly hardware components needed to estimate the ...
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017 The Global Implantable ... CAGR of around 7.5% over the next decade ... of the prominent trends that the market is ... diseases & graft transplant surgeries and medical implants ... market is categorized into immunomodulatory biomaterials, natural, polymers, ...
(Date:1/17/2017)... --  Pulmatrix, Inc . (NASDAQ: PULM ), ... to address serious pulmonary diseases, today announced that its ... of CF patients, PUR1900, has been designated as a ... & Drug Administration. Under the QIDP ... of novel drugs against important pathogens, Pulmatrix will receive ...
(Date:1/17/2017)... N.Y. , Jan. 17, 2017  Northwell ... speed the advance of precision cancer research. ... largest health care provider, Northwell Health ... year. Indivumed, GmbH is a Germany ... anti-cancer medical therapies. Together they will greatly expand ...
(Date:1/17/2017)... Shanghai and Hong Kong (PRWEB) , ... January ... ... innovation lifecycle management software, and NetDimensions, a global provider of learning and performance ... reseller agreement for the mainland China market. , “In the life sciences industry, ...
Breaking Biology Technology: